Fig. 4

Prognostic significance of c-Jun in neuroblastoma. (A-H). Kaplan-Meier plots of overall survival (OS) and event-free survival (EFS) with p values corrected for multiple testing (Bonferroni correction) in four independent neuroblastoma patient cohorts, RPM/SEQC (n = 498; GEO: GSE62564), Kocak (n = 649; GEO: GSE45547), AMC/Versteeg (n = 88; GEO: GSE16476 88/122) and Oberthuer (n = 251; ArrayExpress: E-TABM-38). (I). Correlation of c-Jun expression with patients’ survival (n = 55) or not (n = 33) in AMC/Versteeg (n = 88; GEO: GSE16476 88/122). (J). Expression of c-Jun in patient death from tumor(yes) or not (no death, nd) in two different patient cohorts RPM/SEQC and AMC/Versteeg. (K). Correlation of c-Jun expression with high-risk of neuroblastoma (n = 176) or not (n = 322) in RPM/SEQC. Data in I, J and K were analyzed with unpaired t-test, *p < 0.05, **p < 0.01, ****p < 0.0001. (L). Box plot of c-Jun expression levels in stage (st) 1–4 S tumors in three database, RPM/SEQC, Kocak and AMC/Versteeg. Data were analyzed using one-way ANOVA with Dunnett’s multiple comparisons test, ***p < 0.001, ****p < 0.0001